RecruitingPhase 4ACTRN12624000040561

Effectiveness of Psychedelic Therapy for Treatment Resistant Depression (TRD)


Sponsor

Dr and A/ Professor Ranil Gunewardene

Enrollment

30 participants

Start Date

Dec 4, 2023

Study Type

Interventional

Conditions

Summary

We intend to measure the effectiveness of psilocybin when combined with talking therapy for the treatment of Treatment Resistant Depression (TRD) in real world patient groups We will test how effective psilocybin is for TRD and treat patients who have had limited benefit from existing treatments for these hard to treat conditions


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This trial is measuring how effective psilocybin-assisted therapy is for people with treatment-resistant depression (TRD) — that is, depression that has not responded adequately to at least two different standard antidepressant treatments. Psilocybin is a naturally occurring compound found in certain mushrooms that, when given in a controlled clinical setting alongside supportive talking therapy, has shown promise in research studies for reducing depression symptoms, sometimes with lasting benefit after just one or two sessions. This is a real-world effectiveness study, meaning it is designed to see how well psilocybin therapy works in everyday clinical practice rather than in tightly controlled laboratory conditions. Participants will receive psilocybin combined with structured psychotherapy, and their mental health outcomes will be tracked over time. The study aims to generate evidence that could support wider access to this treatment in Australia. You may be eligible if you are aged 18 to 65 and have treatment-resistant depression. You are not eligible if you have uncontrolled high blood pressure, unstable diabetes, a significant heart condition, epilepsy, a history of stroke, liver disease, low body weight (under 48 kg), or are pregnant. People with a history of psychosis or who are currently using illegal drugs are also excluded.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Psilocybin medicines are given orally in a capsule form once in the morning on the medicine days only. The medicine dosing is by the treating psychiatrist, and he will ensure the patient has swallowed

Psilocybin medicines are given orally in a capsule form once in the morning on the medicine days only. The medicine dosing is by the treating psychiatrist, and he will ensure the patient has swallowed the medicine at dosing. No other strategies are available or indicated. The medicines used are psilocybin for Treatment Resistant Depression. Medicine days occur 2-3 times (depending on response to treatment) interspersed with psychotherapy: ie 3 Preparatory sessions/1 Medicine Day/3 Integration Sessions 1 week apart/ 1 Medicine Day/ 3 Integration Sessions 1 week apart/ Then an optional 3rd Medicine Day and 3 Integration Sessions 1 week apart, if there's an inadequate response to treatment Psilocybin (25mg + optional 10mg) given once in morning on 2-3 medicine days through the treatment interspersed with psychotherapy. The usual dose will be 25mg. 10mg top up will only be if there is an inadequate clinical response to the 25mg dose. Psychotherapy (all sessions are 1 hour) • Three preparation sessions held approximately a week apart. Dr Ranil Gunewardene will conduct the first preparation session 1:1 in rooms or via Zoom for 60 minutes. During this session, further in depth assessment will take place and medical review. The second and third preparation session will be with a HREC approved Psychologist/ psychotherapist 1:1 either in rooms or via Zoom for 1 hour each. • One Dosing session ( approximately 6-7 hours face to face) where supportive, client centered psychotherapy is provided during the dosing experience at Northern Beaches Hospital Clinic Rooms. Psychiatrist Dr Ranil Gunewardene will conduct the administration of medicine, regular monitoring and medical supervision of the client. Dr Ranil Gunewardene will provide direct client time face to face as clinically required. The designated treating HREC approved Psychologist/ Psychotherapist will work face to face with the client throughout their dosing day providing client centered psychotherapy. • Three Integration sessions conducted 1:1 by HREC approved the psychologist/ psychotherapist with the first one held the day after the dosing session and then held approximately a week apart. • Who: HREC approved Psychologists/Psychotherapists conducting the preparation sessions, dosing and integration therapy sessions are all fully registered and have additional training in psychedelic assisted therapy. Mode of Administration: Preparation and Integration sessions will be 1:1 with a psychologist/ psychotherapist or psychiatrist and will be offered either face to face or via Zoom for 60 minutes. Monitoring: • The treatment dyad consisting of Dr Ranil Gunewardene and one of the HREC approved PAT trained psychologists/psychotherapists will be consistent across the course of the treatment and will ensure follow up any non attendance at appointments with telephone contact from the clinic to support adherence to the full therapy program. • A spreadsheet that records client dates of sessions and disengagement from the therapy program prior to completion will be recorded along with action taken to re-engage the client. • Adverse Events will be recorded and reported to HREC and TGA • Pre and post psychometric measures will be administered. Psychedelic Assisted Psychotherapy for Psilocybin is taught during Psychedelic Assisted Therapy training programs that have been completed by all of the psychologists/psychotherapists and the psychiatrist delivering the service. In Summary the therapy approach for all sessions is simply supportive psychotherapy based. There is psychoeducation delivered and set setting and relationship building is undertaken. The therapist is encouraged to stay out of the way of the patient’s medicine guided realisations and perspective shifts. To be guided by the patient’s experiences not the therapist’s agenda. To encourage the rediscovering of the wiser self and to promote patient agency. The therapist is there to support the patient rediscovering and connecting to their “inner healing intelligence”. There are principles of emotional support, encouragement, validation of experiences and perspectives, exploration of feeling states, in a non directive and non judgmental therapist stance.


Locations(1)

NSW, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12624000040561


Related Trials